<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>9926.HK - Akeso Inc. | Equity Research Report</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: #1a1a2e;
            color: #eee;
            line-height: 1.6;
            padding: 20px;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        header {
            background: linear-gradient(135deg, #16213e 0%, #1a1a2e 100%);
            border-radius: 12px;
            padding: 30px;
            margin-bottom: 30px;
            border: 1px solid #0f3460;
        }
        .header-top {
            display: flex;
            justify-content: space-between;
            align-items: center;
            flex-wrap: wrap;
            gap: 20px;
        }
        .ticker-info h1 { font-size: 2.5em; color: #e94560; margin-bottom: 5px; }
        .ticker-info h2 { font-size: 1.2em; color: #aaa; font-weight: normal; }
        .recommendation-badge {
            padding: 15px 30px;
            border-radius: 8px;
            font-size: 1.5em;
            font-weight: bold;
            text-transform: uppercase;
        }
        .badge-buy { background: #00b894; color: #fff; }
        .badge-hold { background: #fdcb6e; color: #333; }
        .badge-sell { background: #d63031; color: #fff; }
        .price-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
            gap: 20px;
            margin-bottom: 30px;
        }
        .price-card {
            background: #16213e;
            border-radius: 10px;
            padding: 20px;
            text-align: center;
            border: 1px solid #0f3460;
        }
        .price-card.highlight { border-color: #e94560; }
        .price-card .label {
            font-size: 0.85em;
            color: #888;
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 8px;
        }
        .price-card .value { font-size: 1.8em; font-weight: bold; }
        .price-card .value.current { color: #e94560; }
        .price-card .value.target { color: #4ea8de; }
        .price-card .value.bull { color: #00b894; }
        .price-card .value.bear { color: #d63031; }
        .upside { color: #00b894; font-size: 0.9em; margin-top: 5px; }
        .downside { color: #d63031; font-size: 0.9em; margin-top: 5px; }
        .section {
            background: #16213e;
            border-radius: 12px;
            padding: 25px;
            margin-bottom: 25px;
            border: 1px solid #0f3460;
        }
        .section h3 {
            color: #e94560;
            font-size: 1.4em;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 2px solid #0f3460;
        }
        .section h4 { color: #4ea8de; margin: 15px 0 10px 0; }
        .thesis-text { color: #ccc; font-size: 1.05em; line-height: 1.8; }
        .metrics-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
            gap: 15px;
            margin: 20px 0;
        }
        .metric {
            background: #1a1a2e;
            padding: 15px;
            border-radius: 8px;
            text-align: center;
        }
        .metric .label { color: #888; font-size: 0.8em; }
        .metric .value { color: #4ea8de; font-size: 1.3em; font-weight: bold; margin-top: 5px; }
        .risk-item {
            background: #1a1a2e;
            border-left: 4px solid #e94560;
            padding: 15px;
            margin-bottom: 15px;
            border-radius: 0 8px 8px 0;
        }
        .risk-item h5 { color: #fff; margin-bottom: 8px; }
        .risk-item p { color: #aaa; font-size: 0.95em; }
        .catalyst-item {
            background: #1a1a2e;
            border-left: 4px solid #00b894;
            padding: 15px;
            margin-bottom: 15px;
            border-radius: 0 8px 8px 0;
        }
        .catalyst-item.negative { border-left-color: #d63031; }
        .catalyst-item h5 { color: #fff; margin-bottom: 8px; }
        .catalyst-item p { color: #aaa; font-size: 0.95em; }
        .probability {
            display: inline-block;
            background: #0f3460;
            color: #4ea8de;
            padding: 2px 8px;
            border-radius: 10px;
            font-size: 0.8em;
            margin-left: 10px;
        }
        table { width: 100%; border-collapse: collapse; margin: 15px 0; }
        th, td { padding: 12px; text-align: left; border-bottom: 1px solid #0f3460; }
        th { background: #0f3460; color: #4ea8de; }
        tr:hover { background: rgba(78, 168, 222, 0.1); }
        .debate-round {
            background: #1a1a2e;
            border-radius: 10px;
            padding: 20px;
            margin-bottom: 15px;
        }
        .debate-round h5 { color: #e94560; margin-bottom: 15px; }
        .bull-view { border-left: 3px solid #00b894; padding-left: 15px; margin: 10px 0; }
        .bear-view { border-left: 3px solid #d63031; padding-left: 15px; margin: 10px 0; }
        .synthesis { border-left: 3px solid #4ea8de; padding-left: 15px; margin: 10px 0; background: rgba(78, 168, 222, 0.1); padding: 15px; border-radius: 0 8px 8px 0; }
        .consensus-item {
            background: rgba(78, 168, 222, 0.1);
            border-left: 3px solid #4ea8de;
            padding: 12px 15px;
            margin-bottom: 10px;
            border-radius: 0 8px 8px 0;
            color: #ccc;
        }
        footer { text-align: center; padding: 30px; color: #666; font-size: 0.9em; }
        .grid-2 {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
        }
        .highlight-box {
            background: linear-gradient(135deg, #2d5a87 0%, #1e3a5f 100%);
            border-radius: 10px;
            padding: 20px;
            margin: 20px 0;
            border-left: 4px solid #00b894;
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <div class="header-top">
                <div class="ticker-info">
                    <h1>9926.HK</h1>
                    <h2>Akeso Inc.</h2>
                    <p style="color: #4ea8de; margin-top: 10px;">Healthcare - Biotechnology / Immuno-Oncology</p>
                </div>
                <div class="recommendation-badge badge-buy">BUY</div>
            </div>
        </header>

        <div class="highlight-box">
            <p style="color: #fff; font-size: 1.1em;"><strong>Key Highlight:</strong> Akeso's cadonilimab (PD-1/CTLA-4 bispecific) is a differentiated asset with best-in-class potential in multiple tumor types. The Summit partnership with Pfizer validates global value.</p>
        </div>

        <div class="price-grid">
            <div class="price-card highlight">
                <div class="label">Current Price</div>
                <div class="value current">HKD 121.00</div>
                <div style="color: #888; font-size: 0.8em; margin-top: 5px;">Verified Jan 2026</div>
            </div>
            <div class="price-card">
                <div class="label">Target Price</div>
                <div class="value target">HKD 140.00</div>
                <div class="upside">+15.7% upside</div>
            </div>
            <div class="price-card">
                <div class="label">Prob-Weighted Value</div>
                <div class="value target">HKD 155.00</div>
                <div class="upside">+28.1% upside</div>
            </div>
            <div class="price-card">
                <div class="label">Bull Case</div>
                <div class="value bull">HKD 220.00</div>
                <div class="upside">+81.8% upside</div>
            </div>
            <div class="price-card">
                <div class="label">Bear Case</div>
                <div class="value bear">HKD 75.00</div>
                <div class="downside">-38.0% downside</div>
            </div>
        </div>

        <div class="section">
            <h3>Investment Thesis</h3>
            <p class="thesis-text">
                Akeso is a leading Chinese immuno-oncology biotech with a differentiated pipeline anchored by cadonilimab (PD-1/CTLA-4 bispecific). At HKD 121, investors gain exposure to a potentially best-in-class immuno-oncology asset with multiple approved indications and a robust pipeline.
            </p>
            <p class="thesis-text" style="margin-top: 15px;">
                <strong>Key Differentiation:</strong> Cadonilimab is the world's first approved PD-1/CTLA-4 bispecific antibody, offering potential advantages over combination therapies with improved safety profile and convenience.
            </p>
            <p class="thesis-text" style="margin-top: 15px;">
                <strong>Global Validation:</strong> The Summit Therapeutics partnership (license for ex-China rights) validates cadonilimab's global potential and provides significant milestone and royalty upside.
            </p>
            <div class="metrics-grid">
                <div class="metric">
                    <div class="label">Conviction</div>
                    <div class="value">MEDIUM-HIGH</div>
                </div>
                <div class="metric">
                    <div class="label">Time Horizon</div>
                    <div class="value">12-24 mo</div>
                </div>
                <div class="metric">
                    <div class="label">Position Size</div>
                    <div class="value">2-4%</div>
                </div>
                <div class="metric">
                    <div class="label">Peak Sales Est.</div>
                    <div class="value">$5B+ Global</div>
                </div>
            </div>
        </div>

        <div class="section">
            <h3>Valuation Scenarios (Recalculated from HKD 121.00)</h3>
            <table>
                <thead>
                    <tr>
                        <th>Scenario</th>
                        <th>Probability</th>
                        <th>Price Target</th>
                        <th>vs Current</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Bull - Global leadership, multiple blockbusters</td>
                        <td>20%</td>
                        <td>HKD 220.00</td>
                        <td style="color: #00b894;">+81.8%</td>
                    </tr>
                    <tr>
                        <td>Base Optimistic - Strong China execution + ex-China milestones</td>
                        <td>30%</td>
                        <td>HKD 165.00</td>
                        <td style="color: #00b894;">+36.4%</td>
                    </tr>
                    <tr>
                        <td>Base - Solid China growth, modest ex-China progress</td>
                        <td>30%</td>
                        <td>HKD 130.00</td>
                        <td style="color: #00b894;">+7.4%</td>
                    </tr>
                    <tr>
                        <td>Bear - Competitive pressure, pipeline setbacks</td>
                        <td>15%</td>
                        <td>HKD 75.00</td>
                        <td style="color: #d63031;">-38.0%</td>
                    </tr>
                    <tr>
                        <td>Super Bear - Clinical failures, market share loss</td>
                        <td>5%</td>
                        <td>HKD 45.00</td>
                        <td style="color: #d63031;">-62.8%</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="section">
            <h3>Key Risks</h3>
            <div class="grid-2">
                <div class="risk-item">
                    <h5>PD-1/CTLA-4 Competitive Landscape <span class="probability">High</span></h5>
                    <p>Multiple bispecific antibodies in development globally could erode differentiation.</p>
                </div>
                <div class="risk-item">
                    <h5>China Healthcare Policy <span class="probability">Medium-High</span></h5>
                    <p>NRDL pricing negotiations and VBP expansion could compress margins.</p>
                </div>
                <div class="risk-item">
                    <h5>Clinical Trial Risk <span class="probability">Medium</span></h5>
                    <p>Phase 3 trials in new indications could fail to meet endpoints.</p>
                </div>
                <div class="risk-item">
                    <h5>Summit Partnership Execution <span class="probability">Medium</span></h5>
                    <p>Ex-China development and commercialization depends on partner execution.</p>
                </div>
            </div>
        </div>

        <div class="section">
            <h3>Catalysts</h3>
            <h4>Positive Catalysts</h4>
            <div class="grid-2">
                <div class="catalyst-item">
                    <h5>Additional Indication Approvals <span class="probability">75%</span></h5>
                    <p>Label expansion in lung cancer, gastric, and other solid tumors.</p>
                </div>
                <div class="catalyst-item">
                    <h5>Summit Phase 3 Readouts <span class="probability">60%</span></h5>
                    <p>Positive global trial data would validate ex-China opportunity.</p>
                </div>
                <div class="catalyst-item">
                    <h5>Revenue Growth Acceleration <span class="probability">65%</span></h5>
                    <p>Continued strong commercial execution in China.</p>
                </div>
            </div>
            <h4>Negative Catalysts</h4>
            <div class="grid-2">
                <div class="catalyst-item negative">
                    <h5>Competitive Data Superiority <span class="probability">30%</span></h5>
                    <p>Competitor bispecific with superior data could pressure positioning.</p>
                </div>
                <div class="catalyst-item negative">
                    <h5>Clinical Setback <span class="probability">20%</span></h5>
                    <p>Trial failure in key indication would impact pipeline value.</p>
                </div>
            </div>
        </div>

        <div class="section">
            <h3>Debate Summary</h3>
            <div class="debate-round">
                <h5>Key Disagreement: Competitive Differentiation Sustainability</h5>
                <div class="bull-view">
                    <strong style="color: #00b894;">BULL:</strong> First-mover advantage with approved bispecific creates clinical data moat. Safety profile advantages over ipilimumab combinations are meaningful for physician adoption.
                </div>
                <div class="bear-view">
                    <strong style="color: #d63031;">BEAR:</strong> Multiple competitors developing similar bispecifics will erode differentiation. Large pharma combinations have established positions.
                </div>
                <div class="synthesis">
                    <strong style="color: #4ea8de;">SYNTHESIS:</strong> Near-term first-mover advantage is real, but long-term differentiation requires continued clinical data superiority and commercial execution.
                </div>
            </div>
        </div>

        <div class="section">
            <h3>Key Consensus Points</h3>
            <div class="consensus-item">Cadonilimab has genuine differentiation as first approved PD-1/CTLA-4 bispecific</div>
            <div class="consensus-item">Summit partnership validates global potential and provides milestone upside</div>
            <div class="consensus-item">China immuno-oncology market is large and growing despite pricing pressure</div>
            <div class="consensus-item">Pipeline depth beyond cadonilimab provides optionality</div>
            <div class="consensus-item">At HKD 121, valuation reflects meaningful growth expectations that require execution</div>
        </div>

        <footer>
            <p>Multi-AI Equity Debate Report | Generated January 2026</p>
            <p>Verified Current Price: HKD 121.00 | This report is for informational purposes only.</p>
            <p style="margin-top: 15px;">
    <a href="9926_HK_Akeso_detailed.html" style="color: #00b894; font-weight: bold; margin-right: 20px;">üìä View Full Detailed Report</a>
    <a href="index.html" style="color: #4ea8de;">‚Üê Back to Portfolio Overview</a>
</p>
        </footer>
    </div>
</body>
</html>
